Day One Biopharmaceuticals Inc DAWN Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 10, 2023 (filed on Mar 14, 2023)

Insider Name:

Blackman Samuel C.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,000

Price:

$18.05
Mar 07, 2023 (filed on Mar 08, 2023)

Insider Name:

Bender Jeremy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,500

Price:

$20.01
Mar 01, 2023 (filed on Mar 03, 2023)

Insider Name:

Grant Julie Papanek

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-25,000

Price:

$18.61
Feb 17, 2023 (filed on Feb 21, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-9,377

Price:

$20.03
Feb 16, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-930

Price:

$19.57
Feb 16, 2023 (filed on Feb 17, 2023)

Insider Name:

Blackman Samuel C.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-674

Price:

$19.57
Feb 16, 2023 (filed on Feb 17, 2023)

Insider Name:

Bender Jeremy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,022

Price:

$19.57
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,250

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,375

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,250

Price:

--

Filings by filing date

Mar 10, 2023 (filed on Mar 14, 2023)

Insider Name:

Blackman Samuel C.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,000

Price:

$18.05
Mar 07, 2023 (filed on Mar 08, 2023)

Insider Name:

Bender Jeremy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,500

Price:

$20.01
Mar 01, 2023 (filed on Mar 03, 2023)

Insider Name:

Grant Julie Papanek

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-25,000

Price:

$18.61
Feb 17, 2023 (filed on Feb 21, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-9,377

Price:

$20.03
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,250

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,375

Price:

--
Feb 16, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-930

Price:

$19.57
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,250

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

York Charles N II

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

1,375

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

Blackman Samuel C.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,437

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	2000 Sierra Point Parkway, Suite 501 BRISBANE CA 94080-1930
Tel:	N/A
Website:	https://dayonebio.com
IR:	See website

Key People

Garry A. Nicholson Chairman of the Board	Jeremy Bender President, Chief Executive Officer, Director	Samuel Blackman Co-Founder, Chief Medical Officer
Charles N. York Chief Financial Officer, Chief Operating Officer, Secretary

Business Overview

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The Company seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. It has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.

Financial Overview

For the fiscal year ended 31 December 2022, Day One Biopharmaceuticals Inc revenues was not reported. Net loss decreased 17% to $142.2M. Lower net loss reflects Interest Income(expense) - Net increase from $4K to $4.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$4.62 to -$2.17.

Employees:	121 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$598.91M as of Dec 31, 2022
Annual revenue (TTM):	$0.00M as of Dec 31, 2022
EBITDA (TTM):	-$146.85M as of Dec 31, 2022
Net annual income (TTM):	-$142.18M as of Dec 31, 2022
Free cash flow (TTM):	-$109.90M as of Dec 31, 2022
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	73,587,094 as of Mar 1, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization